Zusammenfassung
Zur Klarstellung, was Osteoporose nicht ist:
-
eine von der Pharmaindustrie erfundene Krankheit,
-
nur dünner Knochen ohne Krankheitswert,
-
ein normaler, nicht beeinflussbarer Alterungsprozess,
-
eine nicht vermeidbare Erkrankung postmenopausaler Frauen und älterer Personen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ahlborg H, Johnell 0, Turner C et al. (2003) DeBone loss and bone size after menopause. Engl J Med 349:327–334
Bouxsein M (2003) DeBone quality: where do we go from here? Osteoporos Int 14:118–127
Chavassieux P, Arlot M, Reda C, Wei L, Yates A, Meunier P (1997) DeHistomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1000:1475–1480
Currey J (2003) DePerspective: How well are bones designed to resist fracture. J Bone Miner Res 18:591–598
Epstein S, InzerilloA, Caminis J, Zaidi M (2003) DeReview: Disorders associated with acute rapid and severe bone loss. J Bone Miner Res 18:2083–2094
Manolagas S (2000) DeBirth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenensis and treatment of osteoporosis. Endocrine Reviews 21:115–137
Port L, Center J, Briffa K et al. (2003) DeOsteoporotic fracture: missed opportunity for intervention. Osteoporos Int 14:780–784
Sherman P (2003) DeOsteoporosis and young women. Curr Opin Orthop 14:440–444
Stone K, Seeley D, Lui L et al. (2003) DeBMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res 18:1947–1954
Turner C (2002) DeBiomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97–104
Van Staa T, Leufkens H, Cooper C (2002) DeDoes a fracture at one site predict later fractures at other sites? A british cohort study. Osteoporos Int 13:624–629
Van Staa T, Leufkens H, Cooper C (2002) DeThe epidemiology of corticosteroidinduced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787
Young M (2003) DeBone matrix proteins: their function, regulation, and relationship to osteoporosis. Osteoporos Int 14(Suppl3)35–42
Zaidi M, Blair H, Moonga B et al. (2003) DeOsteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 18:599–609
Zaidi M, Moonga B, Sun 1 et al. (2003) DeUnderstanding osteoclast formation and function: implications for future therapies for osteoporosis. Curr Opin Orthop 14:341–350
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bartl, R., Bartl, C. (2004). Definition. In: Osteoporose-Manual. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18792-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-18792-6_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-20892-1
Online ISBN: 978-3-642-18792-6
eBook Packages: Springer Book Archive